Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. - Wikidata - awgldk - TriplyDB

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

http://www.wikidata.org/entity/Q54530545

about

Mast Cell-Targeted Strategies in Cancer Therapy Novel agents for multiple myeloma to overcome resistance in phase III clinical trials KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome.Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.Paediatric mastocytosis: a systematic review of 1747 cases.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.Targeted Treatment Options in Mastocytosis.Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.

P2860

Q26743796-A7589FAD-F7DB-43BF-AD13-604430FB5D7A Q26822754-3147EBB8-FBF1-4B29-9BF8-C8B4529C49F7 Q26830207-AE2ACA3E-D9E2-449E-8FDE-D9B30D7C564F Q27026581-A93D770E-0E98-49D6-9697-560AB0B93028 Q31082982-EF8EDC2F-2E9A-4AB4-A5F0-5504E1E724C9 Q34137971-7F87AFCF-6BFF-4DB5-ACE1-F5EC61284639 Q34774854-5A02102F-9A2B-4DAC-92CE-2E9A18690508 Q36210845-B0835A39-286E-414F-80E0-DF4AB18D8FD2 Q36730397-B5C579DD-C092-4108-856D-B52654A6F096 Q37016233-DCDDB8BA-40E4-4B19-ACCE-1E8BE57D3571 Q37142455-5AD68C62-09AB-417D-8DF3-D28BAA7CABE5 Q38045311-0527AFD9-EE6B-4D18-94CC-81A5EF91D6E0 Q38348047-6000B5D3-CF1D-4ED6-A45A-ED20565AA132 Q38370943-5A07BE0A-FBDC-4723-BF4A-FB380CC6F621 Q39015818-42E9D713-0761-4F64-A69B-34285A35C506 Q41061871-EFACA6D4-76DF-461F-B3E2-3F84984DF32E Q47429067-CC28FD33-C3A3-4718-87EF-4B420568A084 Q51754351-170BEF3E-A3CC-4E7F-B627-3FA1A3725FAA Q55286285-EC3A444A-1289-475F-A4DA-96BA517A4CC5

P2860

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

http://www.wikidata.org/entity/Q54530545

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@en

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@nl

type

label

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@en

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@nl

prefLabel

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@en

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@nl

P1433

Q54530545-799123F8-D7A5-4462-B398-C53CFB3F41C0

P1476

Q54530545-E89FC226-972C-4FB3-AA99-0126B47B2705

P2093

Q54530545-0937BCEC-58E5-4788-80E1-062B243F68D9

Q54530545-095CC6EA-9A1A-4A60-A581-3F71E558056A

Q54530545-33AC9EFD-DDE0-4180-BB6F-199A107DF56B

Q54530545-59FB85B8-7324-42A5-9413-FDBD23180F7C

Q54530545-6B8D087A-FF84-4D6D-9700-5E928D818F79

Q54530545-907FD046-1003-4ABF-8BE7-CA7310409174

Q54530545-90A185D2-7A27-4281-B4AC-CDAA8CCB1510

Q54530545-9542E974-59A9-4AC7-AB1E-3F65D1F0B2B8

Q54530545-A331DD88-168A-4F1F-9F7F-31521290518C

Q54530545-BD197401-96BE-4487-8A6A-E05E0B98E5F8

P2860

Q54530545-016F732E-7EF0-419C-AB02-89F9474147AC

Q54530545-0D87E30F-CE2D-4791-A88C-56F4A061E48B

Q54530545-1EB76F73-8152-48ED-9D9C-909AEF7EAE42

Q54530545-25CC6F54-A52E-455D-A92D-B663B7304DDA

Q54530545-37E70083-70E7-4490-8DF4-D8141695C611

Q54530545-3E8D91F9-999B-4E0B-BADD-8D39456491C5

Q54530545-3FE8ED4B-91B1-4EA5-B89D-6C0C0742F2E3

Q54530545-421FE10C-6745-4ED7-8813-FC09E3543A7D

Q54530545-554D6BB0-C0AE-4323-A710-ECC606C4DE6D

Q54530545-6F04BD31-C901-416B-8B29-3ADE39A498F9

P304

Q54530545-77732D7E-F33E-4BA8-8A5F-D4CB2EB97F6E

P31

Q54530545-B44A43CA-812F-4B72-825F-99CE791A483F

P356

Q54530545-7C72E5FE-76A8-46F9-A77A-BE87F1383248

P433

Q54530545-D2D630B2-55DC-4CAD-A9A7-D871A74ADF76

P478

Q54530545-64B3D7F9-108B-4736-9C18-CBB10B587DF3

P50

Q54530545-74ECFDEE-A031-44FC-AEBE-EEAF5A95B473

Q54530545-A122182B-09A4-4295-8B28-3C98A6BD48C3

Q54530545-A26513C3-B04D-48E4-9B58-BD58EA90FE97

Q54530545-C3AD294D-1F26-4D15-8458-53BEF7D6C59C

Q54530545-EE63A833-0904-4A74-9DE4-97050672746F

P577

Q54530545-ADB32E80-1CF9-40B1-B5DE-95DEC4917836

P5875

Q54530545-34C799BE-48A0-4CD3-B1BB-BDA48FF20BB2

P698

Q54530545-3A15AC0C-B9C0-420E-8743-A65C0897A508

P921

Q54530545-331A2EAD-F2D7-4DF1-AE99-3CC1E32B2715

Q54530545-F15D40AA-A9CF-4CE9-8E2F-EDE707F10C01

P356

J.1600-0609.2012.01761.X

P1433

European Journal of Haematology

P1476

Mast cell leukemia: identifica ...... Kit tyrosine kinase inhibitor.

@en

P2093

Achille Aouba

http://www.w3.org/2001/XMLSchema#string

Alain Moussy

http://www.w3.org/2001/XMLSchema#string

Chantal Brouze

http://www.w3.org/2001/XMLSchema#string

Colin D Mansfield

http://www.w3.org/2001/XMLSchema#string

Danielle Canioni

http://www.w3.org/2001/XMLSchema#string

Elizabeth Macintyre

http://www.w3.org/2001/XMLSchema#string

Felipe Suarez

http://www.w3.org/2001/XMLSchema#string

Frédéric Feger

http://www.w3.org/2001/XMLSchema#string

Katia Hanssens

http://www.w3.org/2001/XMLSchema#string

Ludovic Lhermitte

http://www.w3.org/2001/XMLSchema#string

P2860

Case-control cohort study of patients' perceptions of disability in mastocytosis

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model

Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Mast cells and mast cell neoplasia: a review.

Diagnosis and treatment of systemic mastocytosis: state of the art.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Classification and diagnosis of mastocytosis: current status.

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

P304

47-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2012.01761.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Patrice Dubreuil

Yves Lepelletier

Marie-Olivia Chandesris

P577

2012-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221822818

http://www.w3.org/2001/XMLSchema#string

P698

22324351

http://www.w3.org/2001/XMLSchema#string

P921